Processing...
All Trials
Search
Search
There are 1601 active trials in our database.
Click on a trial to see more information.
1601 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with metastatic castration‑resistant prostate adenocarcinoma after at least one AR‑targeted therapy and a taxane (and PARPi for BRCA1/2 or CPI for MSI‑H/dMMR as applicable) receive lymphodepletion followed by a single infusion of AZD0754, an autologous STEAP2‑targeted CAR T‑cell therapy armored with a dominant‑negative TGF‑βRII. Bridging therapy may be used during manufacturing; key exclusions include prior CAR‑T/STEAP2 therapy and brain metastases.
ClinicalTrials.gov ID: NCT06267729
TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma after at least one novel hormonal agent and typically prior taxane therapy receive ABBV-969 monotherapy, an intravenous dual-targeting antibody–drug conjugate against PSMA and STEAP1 delivering a topoisomerase-1 inhibitor payload. Requires measurable/evaluable metastasis, castrate testosterone, adequate organ function; excludes significant cardiac/pulmonary disease and unresolved ≥Grade 2 toxicities.
ClinicalTrials.gov ID: NCT06318273
TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma after at least one taxane and one AR-targeted therapy receive oral INV-9956, a CYP11A1 inhibitor that blocks the first step of steroidogenesis to further suppress androgen signaling, given with mandatory dexamethasone and fludrocortisone replacement. Open-label dose escalation followed by expansion to define dose, safety, PK/PD, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT06609005
TrialFetch AI summary: Men with progressive metastatic castration-resistant prostate cancer after at least one taxane and one AR-targeted therapy (177Lu-PSMA-617 allowed; ECOG 0–2; excludes prior PD-1/PD-L1 progression or prior cabozantinib) receive cabozantinib 40 mg daily plus nivolumab 480 mg IV q4w. Cabozantinib is a multi-kinase inhibitor (MET/VEGFR2/AXL) with anti-angiogenic and bone microenvironment effects, combined with the PD-1 inhibitor nivolumab to potentially enhance immune response.
ClinicalTrials.gov ID: NCT05502315
TrialFetch AI summary: Adults with PSMA-positive metastatic castration-resistant prostate cancer after ARSI/CYP17 inhibitor and typically 1–2 taxanes receive intravenous [225Ac]Ac-FL-020, a PSMA-targeted alpha-emitting radiopharmaceutical delivering actinium-225 to induce DNA double-strand breaks. Single-arm dose-escalation/expansion assesses safety, PK/dosimetry (with [111In]In-FL-020 in a subset), and preliminary activity.
ClinicalTrials.gov ID: NCT06492122
TrialFetch AI summary: Adults with PSMA-PET–positive metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) after at least one novel androgen‑axis therapy and taxane exposure per cohort (including a cohort post–177Lu‑PSMA) receive IV 225Ac‑PSMA‑Trillium every 6 weeks up to 4 cycles. 225Ac‑PSMA‑Trillium is a PSMA-targeted small‑molecule alpha radioligand (actinium‑225, macropa chelator with albumin‑binding moiety) designed to enhance tumor uptake and limit salivary exposure by delivering alpha radiation–mediated DNA damage.
ClinicalTrials.gov ID: NCT06217822
TrialFetch AI summary: Adults with metastatic castration-resistant prostate cancer who have progressed on or are intolerant to at least one next-generation hormonal agent and taxane receive ACE-232, an oral non-steroidal CYP11A1 inhibitor that suppresses steroidogenesis to reduce AR signaling. Single-arm, dose-escalation and dose-optimization cohorts are included, with a biomarker-enriched Phase 1B focusing on patients with AR gene alterations.
ClinicalTrials.gov ID: NCT06801236
TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma after at least one novel AR-targeted therapy and 1–2 taxane regimens (ECOG 0–1) receive GSK5458514, a PSMA×CD3 bispecific T‑cell engager redirecting T‑cell cytotoxicity to PSMA-expressing tumors, as monotherapy with possible combination cohorts. Excludes neuroendocrine variants, CNS metastases, prior PSMA CAR‑T/engagers, recent extensive PSMA radioligand therapy, significant autoimmune disease, or active viral hepatitis.
ClinicalTrials.gov ID: NCT06990880
Phase 1/2 Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
TrialFetch AI summary: Eligible adult men with progressive mCRPC on continuous ADT after prior systemic therapy (ECOG 0–1) receive oral HLD‑0915 monotherapy in 21‑day cycles. HLD‑0915 is a first‑in‑class RIPTAC small molecule that leverages androgen receptor as a tumor handle to recruit BRD4 (AR–BRD4 RIPTAC), inducing selective cancer cell death; exclusions include neuroendocrine/small‑cell features and significant bleeding or cardiac disease.
ClinicalTrials.gov ID: NCT06800313
TrialFetch AI summary: Men with localized, histologically confirmed intraprostatic recurrence after prior external-beam or HDR brachytherapy (ECOG 0–1, no nodal/metastatic disease) undergo interstitial photodynamic therapy using the SpectraCure P18 laser with IDOSE planning plus verteporfin. Verteporfin is a benzoporphyrin photosensitizer that accumulates in tumor/neovasculature and, when light-activated, generates reactive oxygen species to induce vascular shutdown and tumor necrosis; patients unsuitable for salvage surgery or curative re-irradiation are eligible.
ClinicalTrials.gov ID: NCT03067051